(10 April 2020) Remdesivir – 36 out of 53 saw improvements

Compassionate Use of Remdesivir for Patients with Severe Covid-19

https://www.nejm.org/doi/full/10.1056/NEJMoa2007016

In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)